EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

Amy H Huang iD, Gin Yi Lee, Chuan Angel Lu iD, Ibrahim Halil Sahin iD, Gentry T King iD, Rachael A Safyan iD, Stacey A Cohen, David B Zhen iD, Veena Shankaran iD, William P Harris, Andrew L Coveler iD, Jyoti Malhotra iD und 4 weitere

JCO Oncology Practice · 2026-10 · 22 (10) · 1701-1712

DOI: 10.1200/op-25-00646 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JCO Oncology Practice, 2026-10. Verfasst von Amy H Huang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Connecticut School of Medicine, Farmington, CT. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colorectal Neoplasms, ErbB Receptors, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Clonal evolution is a mechanism of treatment resistance against epidermal growth factor receptor inhibitors (EGFRi) in metastatic colorectal cancer (mCRC). When EGFRi is discontinued, EGFRi-resistant tumor subclones decay with time, allowing for EGFRi rechallenge at later time. We conducted a meta-analysis to investigate the efficacy of EGFRi rechallenge in mCRC. METHODS Clinical trials and observational studies investigating the efficacy of EGFRi rechallenge in mCRC were included from PubMed and Embase from inception to December 8, 2024. Hazard ratios (HRs) of overall survival (OS) and progression-free survival (PFS) were aggregated using Bayesian random-effects models. Objective response rates (ORRs) were aggregated using meta-random-effects models. RESULTS Twenty-nine studies were included. The pooled median PFS, median OS, and ORR were 3.83 months (95% CI, 3.25 to 4.50), 10.43 months (95% CI, 8.14 to 13.36), and 14.61% (95% CI, 8.70 to 23.51), respectively. EGFRi rechallenge was associated with significantly longer pooled PFS (HR, 0.54 [95% CI, 0.31 to 0.93]) and numerically longer pooled OS (HR, 0.71 [95% CI, 0.46 to 1.09]) than non-EGFRi systemic therapy. Patients without detectable RAS/RAF mutations by circulating tumor DNA (ctDNA) at the time of EGFRi rechallenge had significantly longer OS (HR, 0.43 [95% CI, 0.24 to 0.75]) and PFS (HR, 0.40 [95% CI, 0.26 to 0.62]) than those with ctDNA RAS/RAF mutations. Studies with EGFRi-free intervals ≥4 months before rechallenge (18.77%) had a numerically greater pooled ORR than those with EGFRi-free intervals

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsColorectal NeoplasmsErbB ReceptorsTyrosine Kinase InhibitorsHumansNeoplasm Metastasis

Substanzen

Antineoplastic AgentsEGFR protein, humanErbB ReceptorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Connecticut School of Medicine, Farmington, CT.
  • Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
  • Division of Hematology/Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Irvine, CA.

ORCID-Profile: Amy H Huang, Chuan Angel Lu, Ibrahim Halil Sahin, Gentry T King, Rachael A Safyan, David B Zhen, Veena Shankaran, Andrew L Coveler, Jyoti Malhotra, Victoria E Forbes, E Gabriela Chiorean, Ronan W Hsieh

Zitieren

APA

Huang, A. H., Lee, G. Y., Lu, C. A., Sahin, I. H., King, G. T., Safyan, R. A., Cohen, S. A., Zhen, D. B., Shankaran, V., Harris, W. P., Coveler, A. L., Malhotra, J., Forbes, V. E., Gold, P. J., Chiorean, E. G., & Hsieh, R. W. (2026). Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. JCO Oncology Practice, 22(10), 1701-1712. https://doi.org/10.1200/op-25-00646

Vancouver

Huang AH, Lee GY, Lu CA, Sahin IH, King GT, Safyan RA, et al. Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. JCO Oncology Practice. 2026;22(10):1701-1712. doi:10.1200/op-25-00646

BibTeX
@article{Huang2026,
  author = {Huang, Amy H and Lee, Gin Yi and Lu, Chuan Angel and Sahin, Ibrahim Halil and King, Gentry T and Safyan, Rachael A and Cohen, Stacey A and Zhen, David B and Shankaran, Veena and Harris, William P and Coveler, Andrew L and Malhotra, Jyoti and Forbes, Victoria E and Gold, Philip J and Chiorean, E Gabriela and Hsieh, Ronan W},
  title = {Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis},
  journal = {JCO Oncology Practice},
  year = {2026},
  volume = {22},
  number = {10},
  pages = {1701--1712},
  doi = {10.1200/op-25-00646}
}
Kostenlos starten →